Today's Top SOA Links
From the Wires
Aethlon Medical Receives Intent to Issue Notice on European Patent to Remove Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Other Viral Pathogens From Blood
By: PR Newswire
Nov. 6, 2012 09:30 AM
SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the European Patent Office (EPO) has provided the Company a notice of intent to issue European Patent Application No. 04 703 672.8 entitled "Method For Removal of Viruses From Blood By Lectin Affinity Hemodialysis." The patent describes a medical device that incorporates an affinity lectin to reduce the presence of envelope viruses and viral particles from blood or blood plasma.
"As we continue the successful expansion of our intellectual property portfolio, this patent will help to protect a substantial market opportunity for our Hemopurifier® to address Hepatitis C and other infectious disease conditions throughout the European marketplace," stated Aethlon Medical Chairman and CEO, Jim Joyce. The Aethlon Hemopurifier®, which is a first-in-class device being advanced in Hepatitis C care, has demonstrated the ability to capture a broad-spectrum infectious viral pathogens, including HIV and numerous bioterror and pandemic threats.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with DARPA that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies or as a standalone cancer therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to successfully defend its intellectual property portfolio in the United States or in the European Union, the Company's ability to realize commercial opportunities in the European Union, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
James A. Joyce
SOURCE Aethlon Medical, Inc.
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week